Pfizer Inc (PFE) stock price, news and key stats

Price

Last trade as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$27.55

Open

$27.60

Day range

$27.36 – $27.69

Volume

1.7M

52-week range

$23.58 – $29.21

Market cap

$157B

Forward P/E

9.5

Dividend yield

620.00%

Beta

0.30

Avg. volume

41.8M

Analyst target

$28.88

Next earnings

Nov 3, 2026

About Pfizer Inc

Latest PFE news

• This BlackRock strategist opposes a Fed hike. Here are the funds she recommends.
  MarketWatch · Sep 16, 2026

  Gargi Pal Chaudhuri, a strategist at BlackRock, has voiced her opposition to a potential interest rate hike by the Federal Reserve, emphasizing the need for a more cautious approach to monetary policy. Chaudhuri argues that raising rates could stifle economic growth, particularly in sectors that are still recovering from the pandemic. Instead, she advocates for investors to maintain their positions in the artificial intelligence sector, which has shown robust growth potential, while also diversifying into themes such as quality investments and healthcare. Chaudhuri's recommendations come at a time when market participants are weighing the implications of the Fed's monetary policy on various asset classes. By focusing on quality and healthcare, she suggests that investors can mitigate risks associated with economic uncertainty, particularly as inflationary pressures continue to influence market dynamics. These sectors are often seen as more resilient during economic downturns, providing a buffer against volatility. As the market anticipates the Fed's next move, Chaudhuri's insights may resonate with investors looking for stability amid fluctuating interest rates. Her emphasis on artificial intelligence aligns with broader trends in technology and innovation, which are expected to drive future growth. Overall, her recommendations reflect a strategic approach that balances growth opportunities with risk management in an uncertain economic landscape.

• Trump Administration Moves to Integrate A.I. Into Medical Care Despite Concerns
  NYT Business · Sep 14, 2026

  The Trump administration is moving aggressively to weave artificial intelligence into the American health care system, pressing federal health agencies, hospitals, and insurers to adopt AI tools for clinical care, administrative work, and drug development even as patient advocates and some medical experts warn the technology is being deployed faster than safeguards can be built. The effort spans the Department of Health and Human Services, the Centers for Medicare and Medicaid Services, and the Food and Drug Administration, and aligns with the White House's broader deregulatory approach to AI, which has emphasized rapid adoption and rolled back guardrails established under the previous administration. Under the push, health officials have courted major technology companies to modernize patient data systems and develop AI-powered tools, while regulators have signaled a lighter touch on AI-enabled medical devices and software. Proponents within the administration argue that AI could ease physician burnout, cut administrative costs, accelerate drug discovery, and help address rural shortages of medical specialists. Critics, including some Democratic lawmakers, patient safety groups, and physicians, counter that the absence of rigorous validation standards raises the risk of biased algorithms, misdiagnoses, and privacy breaches involving sensitive health data. Lawmakers have also scrutinized insurers' use of AI in claims processing, amid lawsuits alleging algorithms were used to improperly cut off coverage for Medicare Advantage patients. For markets, the policy shift is a meaningful tailwind for the fast-growing health AI sector. Companies developing clinical AI, ambient documentation tools, and AI-driven drug discovery platforms stand to benefit from friendlier regulation and federal encouragement, while electronic health record vendors and cloud providers are positioning to capture demand for AI-ready data infrastructure. Investors are watching for concrete regulatory clarity from the FDA on AI device approvals and from CMS on reimbursement, which would determine how quickly adoption translates into revenue. Still, analysts caution that execution risk is high. A backlash over patient harm, data privacy, or denied claims could trigger congressional intervention and new liability exposure, and health systems remain wary of integrating tools that lack clear clinical evidence. The coming months will test whether the administration can scale AI in medicine quickly enough to satisfy its innovation agenda without provoking the safety and trust concerns that have shadowed the technology's entry into patient care.

• Vital Signs: Novartis' mounting M&A headaches
  IPO & M&A · Sep 13, 2026

  Novartis is facing increasing challenges in its mergers and acquisitions (M&A) strategy, as the pharmaceutical giant grapples with regulatory scrutiny and integration issues from recent deals. The company's attempts to bolster its pipeline through acquisitions have been met with skepticism from investors, particularly in light of the complexities involved in assimilating new assets and aligning them with its existing operations. This has raised concerns about the potential for value dilution and the effectiveness of Novartis' long-term growth strategy. Market analysts are closely monitoring Novartis' stock performance in response to these challenges. The company's shares have shown volatility, reflecting investor apprehension regarding its ability to successfully navigate the M&A landscape. Furthermore, the broader pharmaceutical sector is experiencing heightened competition and regulatory pressures, which could exacerbate Novartis' difficulties in executing future transactions. As the company seeks to reassure stakeholders, it may need to adopt a more cautious approach to M&A, focusing on organic growth and innovation rather than aggressive acquisitions.

• 6 Ultra-High-Yield Names Where Coverage Is Cracking - 24/7 Wall St.
  Corporate Bonds · Sep 12, 2026

  Investors seeking high-yield opportunities in a rising interest rate environment may want to consider six ultra-high-yield stocks highlighted by 24/7 Wall St. These companies, including Pfizer (PFE) and United Parcel Service (UPS), offer dividend yields exceeding 6% while maintaining solid cash flow to support their payouts. With the 10-year Treasury yield nearing 5%, many traditional dividend stocks have struggled to attract investors, making these high-yield options particularly appealing. Pfizer and UPS are currently trading over 20% below their five-year price averages, yet both companies' CEOs have assured shareholders of their commitment to sustaining dividends. This stability is crucial as investors weigh the risks associated with high-yield stocks in a potentially volatile market. Additionally, Chevron's impressive $15.4 billion in free cash flow for the second quarter, coupled with a low net debt ratio of 0.6x, further underscores the potential for reliable income generation in this sector. As the market adjusts to higher interest rates, the ability of these companies to generate cash flow without excessive leverage will be key to their long-term viability. Investors should remain vigilant, as any signs of weakening cash flow or increased debt levels could prompt a reassessment of these high-yield investments.

• Triad experts weigh in on the Canadian and US trade war and how it could affect pharmaceuticals
  Geopolitics · Sep 11, 2026

  The ongoing trade tensions between Canada and the United States are raising concerns among industry experts regarding their potential impact on the pharmaceutical sector. As both nations grapple with tariffs and regulatory barriers, the implications for drug pricing, supply chains, and research collaboration are becoming increasingly pronounced. Experts warn that heightened trade disputes could lead to increased costs for pharmaceutical companies, which may ultimately be passed on to consumers in the form of higher drug prices. Moreover, the trade war could disrupt the intricate supply chains that underpin the pharmaceutical industry. Canada is a significant player in the production of active pharmaceutical ingredients (APIs) and generic drugs, and any restrictions on trade could hinder the availability of these essential components in the U.S. market. This disruption could lead to shortages and delays in drug production, further complicating the already challenging landscape of healthcare delivery. In light of these developments, pharmaceutical companies may need to reassess their strategies, potentially shifting production locations or increasing domestic sourcing to mitigate risks associated with trade volatility. Investors should remain vigilant, as the evolving trade dynamics could influence stock valuations within the sector, particularly for companies heavily reliant on cross-border trade. As the situation unfolds, the pharmaceutical industry will be closely monitoring policy changes and seeking ways to adapt to the shifting trade landscape.

• PE Weekly: M&A Roundup Sept. 4-10
  IPO & M&A · Sep 10, 2026

  The week of September 4-10 saw a flurry of mergers and acquisitions activity, signaling a continued robust interest in consolidation across various sectors. Notably, several high-profile deals were announced, including a significant acquisition in the technology sector, where a major software company agreed to purchase a smaller rival for $2.5 billion. This move is expected to enhance the acquirer's market position and expand its product offerings, reflecting a broader trend of strategic acquisitions aimed at bolstering competitive advantages. In the healthcare sector, a prominent pharmaceutical company announced a merger with a biotech firm specializing in rare diseases, valued at approximately $1.8 billion. This transaction highlights the ongoing trend of larger firms seeking to diversify their portfolios and tap into innovative therapies, which could lead to increased market share and improved R&D capabilities. Analysts suggest that such deals may also attract investor interest, as they often signal growth potential and a commitment to advancing healthcare solutions. Market implications of this M&A activity are significant, as they can lead to shifts in stock valuations and investor sentiment. The heightened deal-making environment may indicate a favorable economic outlook, encouraging companies to pursue growth through acquisitions. However, potential regulatory scrutiny remains a concern, particularly for larger transactions, which could impact deal timelines and valuations. Overall, the M&A landscape appears vibrant, with companies actively seeking opportunities to enhance their strategic positions in an increasingly competitive market.

• 2026 Summer review: M&A legal and market developments alert
  IPO & M&A · Sep 10, 2026

  As the summer of 2026 unfolds, the mergers and acquisitions (M&A) landscape is experiencing significant legal and market developments that could reshape the trajectory of corporate consolidation. Regulatory scrutiny remains heightened, particularly in sectors deemed critical to national security and consumer welfare. The Federal Trade Commission (FTC) and the Department of Justice (DOJ) have intensified their review processes, leading to longer timelines for approvals and increased challenges for proposed deals. This regulatory environment is prompting companies to reassess their M&A strategies, with a notable shift towards smaller, less contentious transactions that are more likely to receive regulatory clearance. Market sentiment around M&A activity has been mixed, with a cautious approach prevailing among investors. While some sectors, such as technology and healthcare, continue to see robust deal-making driven by innovation and strategic realignment, others are facing headwinds due to economic uncertainties and rising interest rates. The cost of financing M&A deals has increased, compelling companies to explore alternative funding mechanisms or to prioritize cash reserves. Analysts suggest that this environment could lead to a consolidation wave among smaller firms unable to navigate the changing landscape, potentially creating opportunities for larger players to expand their market share. Overall, the summer of 2026 is shaping up to be a pivotal period for M&A activity, characterized by a complex interplay of regulatory challenges and shifting market dynamics. Stakeholders are advised to remain vigilant as they navigate this evolving landscape, which could have lasting implications for corporate strategies and competitive positioning in the years to come.

• Suddenly, everyone is speaking Trump's language on tariffs
  Macro Watch · Sep 9, 2026

  In a notable shift in economic discourse, a growing number of policymakers and business leaders are increasingly adopting former President Donald Trump's rhetoric on tariffs. This change comes amid rising concerns over supply chain vulnerabilities and the competitive pressures posed by countries like China. As inflationary pressures persist, the idea of using tariffs as a tool to protect domestic industries and jobs is gaining traction, suggesting a potential pivot in trade policy that could have significant implications for the economy. The renewed focus on tariffs is reflected in recent discussions among lawmakers who are considering measures to impose tariffs on a broader range of imports. This shift may be driven by a desire to bolster American manufacturing and reduce dependency on foreign goods, particularly in critical sectors such as technology and healthcare. Market analysts warn that while tariffs can provide short-term relief for domestic producers, they may also lead to increased costs for consumers and retaliatory measures from trading partners, which could further complicate the global trade landscape. Investors are closely monitoring these developments, as a more protectionist trade policy could influence stock market performance and sector-specific dynamics. Industries that rely heavily on imports may face margin pressures, while domestic manufacturers could see a boost in demand. As the political climate evolves, the implications of this renewed tariff dialogue will likely shape economic forecasts and investment strategies in the months to come.

• There are some tremendous healthcare companies in bull market mode, says Jim Cramer
  Market Outlook · Sep 8, 2026

  Jim Cramer, the host of CNBC's "Mad Money," has highlighted a selection of healthcare companies that are currently thriving in what he describes as a bull market. Cramer emphasized that while artificial intelligence continues to capture headlines, investors should not overlook the robust performance and potential of healthcare stocks. He pointed to several firms that are not only showing strong earnings but also exhibiting resilience amid broader market fluctuations. Cramer’s analysis suggests that the healthcare sector is well-positioned for growth, driven by factors such as an aging population, increasing demand for innovative treatments, and advancements in biotechnology. This positive outlook could lead to increased investment in these companies, potentially boosting stock prices and attracting institutional interest. As investors seek to diversify their portfolios beyond tech-driven stocks, Cramer’s insights may encourage a shift towards healthcare, which could further enhance the sector's momentum in the coming months.

• Enhanced FDA-SEC Collaboration: How Life Sciences Companies Think About Disclosure, Insider Trading, and Prediction Markets
  Financial Regulation · Sep 8, 2026

  On August 31, 2026, the U.S. Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) announced a new Memorandum of Understanding (MOU) aimed at enhancing collaboration between the two agencies. This initiative is expected to significantly impact how life sciences companies approach disclosure practices, insider trading, and prediction markets. By fostering a more integrated regulatory environment, the agencies aim to improve the transparency and accuracy of information provided to investors regarding drug approvals and clinical trial results. The MOU signals a proactive stance by regulators to address the complexities of the life sciences sector, where timely and accurate disclosures are critical for investor decision-making. As the FDA continues to evaluate new therapies and treatments, the SEC's involvement will likely lead to stricter scrutiny of disclosures related to clinical outcomes and potential market-moving events. This heightened oversight could deter insider trading and promote fairer market practices, as companies will need to ensure compliance with both agencies' standards. Market implications are substantial, as enhanced regulatory scrutiny may lead to increased volatility in life sciences stocks, particularly around key FDA announcements. Companies will need to adopt more rigorous disclosure protocols to mitigate risks associated with non-compliance. Investors should prepare for a landscape where information asymmetry is reduced, potentially leading to more informed trading strategies and a shift in how market participants assess the value of biotech and pharmaceutical firms.

All 72 articles in the app →

Earnings history

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen